Skip to main content
Article
Insights from immuno-oncology: The Society for Immunotherapy of Cancer statement on access to IL-6-targeting therapies for COVID-19
Society for Immunotherapy of Cancer (SITC)
  • Paolo A Ascierto
  • Bernard A Fox, Chiles Research Institute Providence Portland Medical Center
  • Walter Urba, Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR, 97213, USA.
  • Ana Carrizosa Anderson
  • Michael Atkins
  • Ernest C Borden
  • Julie R Brahmer
  • Lisa H Butterfield
  • Alessandra Cesano
  • Daniel S Chen
  • Tanja D De Gruijl
  • Robert O Dillman
  • Charles G Drake
  • Leisha A Emens
  • Thomas F Gajewski
  • James L Gulley
  • F Stephen Hodi, Jr.
  • Patrick Hwu
  • David Kaufman
  • Howard L Kaufman
  • Michael T Lotze
  • Francesco M Marincola
  • Kim A Margolin
  • Michael J Mastrangelo
  • Marcela V Maus
  • Douglas G McNeel
  • David R Parkinson
  • Pedro J Romero
  • Paul M Sondel
  • Stefani Spranger
  • Mario Sznol
  • George J Weiner
  • Jon M Wigginton
  • Jeffrey S Weber
Document Type
Abstract
Publication Date
3-24-2020
Keywords
  • 2019-nCoV
Disciplines
Abstract

The following statement was posted on March 24, 2020 and updated April 2, 2020. It has been accepted for upcoming publication in the Journal for ImmunoTherapy of Cancer (JITC).

Clinical Institute
Cancer
Specialty
Infectious Diseases
Specialty
Oncology
Specialty
Earle A. Chiles Research Institute
Citation Information
Paolo A Ascierto, Bernard A Fox, Walter Urba, Ana Carrizosa Anderson, et al.. "Insights from immuno-oncology: The Society for Immunotherapy of Cancer statement on access to IL-6-targeting therapies for COVID-19" Society for Immunotherapy of Cancer (SITC) (2020)
Available at: http://works.bepress.com/walter-urba/295/